Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Stock futures fell again Monday, after the S&P 500 had its worst week in months amid fears about President Donald Trump's tariff policy. Mark Carney won the race to replace Justin Trudeau as Canada's ...

Yahoo Finance will chronicle the latest news and updates on Trump's tariffs — from the threats to the eventual policy.

The "U.S. Medical Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering. This report presents a complete picture of the medical weight loss market in the ...